American Heart Association
Testing how well “good” cholesterol particles reduce inflammation may help predict who is at heightened risk to develop cardiovascular disease caused by narrowed arteries, according to research published today in the American Heart Association’s flagship journal Circulation.
Beta-blockers treat various cardiovascular diseases and were not more likely to cause depression compared to other similar treatments, according to new research published today in Hypertension, an American Heart Association journal. While depression may occur during beta-blocker therapy, the research suggests beta-blockers are not the likely cause.
Dietary information from three large, well-known heart disease studies suggests drinking one or more cups of caffeinated coffee may reduce heart failure risk, according to research published today in Circulation: Heart Failure, an American Heart Association journal.
Issue Highlights: Nine manuscripts featuring research from around the world are featured in a special section of the February 2021 issue of the Stroke journal, published online today. The papers address stroke disparities in women including underrepresentation in clinical trials.
American Heart Association and American Medical Society for Sports Medicine collaborate to evaluate impact to heart, improve detection and inform safe return to play.
The American Heart Association and the TCU and UNTHSC School of Medicine collaborate on communications training series for scientists and researchers.
American College of Cardiology/American Heart Association Clinical Practice Guideline
President-elect Biden today announced his nominees for key public health positions in his incoming administration. The American Heart Association, the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke, released the following statement: “We look forward to working with the incoming Biden administration and its experienced public health team to support […]
The American Heart Association and American Medical Association recognize more than 1,000 organizations for efforts to reduce the number of patients with uncontrolled blood pressure
The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm. Researchers concluded that rivaroxaban worked as well as the standard anticoagulant medication warfarin.
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!